Rapid Rx Quiz: Headache Medications

Mary L. Windle, PharmD


September 12, 2022

A recent meta-analysis compared the relative efficacy of lasmiditan for acute treatment of migraines with ubrogepant and rimegepant. Researchers found that lasmiditan is associated mainly with mild to moderate, self-limiting neurologic events. Across 12 randomized controlled trials, the most commonly reported adverse events with lasmiditan were dizziness, fatigue, paresthesia, sedation, nausea, and muscle weakness. With rimegepant, nausea was most common; with ubrogepant, the most common adverse events were somnolence, nausea, and dry mouth. Outcomes for both pain freedom and pain relief for lasmiditan compared with rimegepant and ubrogepant were equal or superior, depending on the dose.

Learn more about lasmiditan.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.